CCL22 and familial pancreatic carcinoma: Transduction of T cells with CCR4, the receptor for CCL22, led to improved interaction of the T cells with dendritic cells (DCs), increased T cell activation and improved T cell tumor penetration in a mouse model [359], suggesting that addition of this chemokine receptor to CAR-T cells intended for treatment of pancreatic cancer might be fruitful.